Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexamethasone (DRd) and bortezomib plus dexamethasone in relapsed and refractory multiple myeloma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Advertisement